A Phase 2 interventional study of Andecaliximab and Placebo in Rheumatoid Arthritis, sponsored by Gilead Sciences. Terminated at 8 sites in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2018-06-27.
Sponsored by Gilead Sciences · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Arthritis, Rheumatoid by Gilead Sciences — none open to participants now, 1 under way, none of them phase 3. Arthritis, Rheumatoid · Gilead Sciences.
Among the 12 studies in Arthritis, Rheumatoid by Gilead Sciences, this one is the 11th largest by enrollment, is one of 6 that started in 2016, is one of 3 in phase 2, and was the 3rd registered.
3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.
Browse Arthritis, Rheumatoid studies →None of the 12 studies in Arthritis, Rheumatoid by Gilead Sciences is open now. The open studies under Arthritis, Rheumatoid, anywhere →
Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2014; this study’s year is marked. 6 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 15 is below the median of 96 across 2,222 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 49 across the 12 interventional studies. Of the 10 that completed or were terminated, 8 (80%) have results posted.
This tab as a report to print or save as PDF → With an account.
Gilead Sciences is the lead sponsor of 692 studies on the registry; 26 are open to participants now.
Of its 261 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.
1 of the studies in Arthritis, Rheumatoid by Gilead Sciences that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06902519Gilead SciencesStudy of GS-0151 in Participants With Rheumatoid Arthritis | 2027-03 |
Add it to your calendar (.ics) → With an account.
Among the 12 studies in Arthritis, Rheumatoid by Gilead Sciences, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary objective of this study is to evaluate the efficacy of andecaliximab (GS-5745) versus placebo as an add-on therapy to a tumor necrosis factor (TNF) inhibitor and methotrexate in adults with moderate to severe rheumatoid arthritis (RA).
Key Inclusion Criteria:
Tuberculosis (TB) Screening: Must meet either a. or b.:
A negative history of TB infection and a negative QuantiFERON® TB-Gold In-Tube test and chest x-ray results. (QuantiFERON® tests with inconclusive results may be repeated one time. If the repeat result is also inconclusive, the individual will be excluded from the study).
OR,
Key Exclusion Criteria:
History of any of the following within 12 months of baseline:
The results of the following laboratory tests performed at the central laboratory at screening meet any of the criteria below:
or a history of malignancy or lymphoproliferative disorder within 10 years of screening with the following exceptions:
Note: Other protocol defined inclusion/exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Andecaliximab 300 mg for 12 weeks, in addition to their current regimen of a TNF inhibitor and methotrexate.
Drug: Andecaliximab · Drug: Methotrexate · Drug: TNF Inhibitor
Andecaliximab 150 mg + placebo for 12 weeks, in addition to their current regimen of a TNF inhibitor and methotrexate.
Drug: Andecaliximab · Drug: Placebo · Drug: Methotrexate · Drug: TNF Inhibitor
Placebo weekly for 12 weeks, in addition to their current regimen of a TNF inhibitor and methotrexate.
Drug: Placebo · Drug: Methotrexate · Drug: TNF Inhibitor
On the Week 12 visit, eligible participants may choose to participate in the open-label portion of the study to receive open-label andecaliximab 300 mg for 52 weeks, in addition to their current regimen of a TNF inhibitor and methotrexate.
Drug: Andecaliximab · Drug: Methotrexate · Drug: TNF Inhibitor
Administered via subcutaneous injection once weekly
Also known as: GS-5745
Administered via subcutaneous injection once weekly
Administered orally weekly as part of the participant's current treatment regimen
An approved stable subcutaneous formulation of one of the following TNF inhibitors may include adalimumab, certolizumab, etanercept, or golimumab.
Change From Baseline in DAS28(CRP) at Week 12
The DAS28 score is a measure of the participant's disease activity calculated using the tender joint counts (28 joints), swollen joint counts (28 joints), Patient's Global Assessment of Disease Activity (visual analog scale: 0 = no disease activity to 100 = maximum disease activity), and CRP for a total possible score of 1 to 9.4. Higher values indicate higher disease activity. A negative change from baseline indicates improvement.
Time frame: Baseline; Week 12
Percentage of Participants That Achieve DAS28(CRP) ≤ 3.2 at Week 12
The DAS28 score is a measure of the participant's disease activity calculated using the tender joint counts (28 joints), swollen joint counts (28 joints), Patient's Global Assessment of Disease Activity (visual analog scale: 0 = no disease activity to 100 = maximum disease activity), and CRP for a total possible score of 1 to 9.4. Higher values indicate higher disease activity. A negative change from baseline indicates improvement.
Time frame: Week 12
Percentage of Participants That Achieve DAS28(CRP) < 2.6 at Week 12
The DAS28 score is a measure of the participant's disease activity calculated using the tender joint counts (28 joints), swollen joint counts (28 joints), Patient's Global Assessment of Disease Activity (visual analog scale: 0 = no disease activity to 100 = maximum disease activity), and CRP for a total possible score of 1 to 9.4. Higher values indicate higher disease activity. A negative change from baseline indicates improvement.
Time frame: Week 12
Plasma Concentration of Andecaliximab
The plasma concentrations of andecaliximab were not collected and were not analyzed.
Time frame: Day 4 or 6 (± 1 day)
Participants were enrolled at study sites in the United States. The first participant was screened on 15 December 2016. The last study visit occurred on 07 August 2017.
| Milestone | Andecaliximab 300 mg | Andecaliximab 150 mg | Placebo |
|---|---|---|---|
| Started | 5 | 5 | 5 |
| Completed | 2 | 3 | 1 |
| Not completed | 3 | 2 | 4 |
| Withdrew: Adverse event | 0 | 1 | 0 |
| Withdrew: Study terminated by sponsor | 3 | 1 | 4 |
| Milestone | Andecaliximab 300 mg | Andecaliximab 150 mg | Placebo |
|---|---|---|---|
| Started | 2 | 3 | 1 |
| Completed | 0 | 0 | 0 |
| Not completed | 2 | 3 | 1 |
| Withdrew: Study terminated by sponsor | 2 | 3 | 1 |
The DAS28 score is a measure of the participant's disease activity calculated using the tender joint counts (28 joints), swollen joint counts (28 joints), Patient's Global Assessment of Disease Activity (visual analog scale: 0 = no disease activity to 100 = maximum disease activity), and CRP for a total possible score of 1 to 9.4. Higher values indicate higher disease activity. A negative change from baseline indicates improvement.
| units on a scale | Andecaliximab 300 mg | Andecaliximab 150 mg | Placebo |
|---|---|---|---|
| Change From Baseline in DAS28(CRP) at Week 12 | 0.13 ± 0.115 | -1.51 ± 0.670 | -0.36 ± 0.353 |
The DAS28 score is a measure of the participant's disease activity calculated using the tender joint counts (28 joints), swollen joint counts (28 joints), Patient's Global Assessment of Disease Activity (visual analog scale: 0 = no disease activity to 100 = maximum disease activity), and CRP for a total possible score of 1 to 9.4. Higher values indicate higher disease activity. A negative change from baseline indicates improvement.
| percentage of participants | Andecaliximab 300 mg | Andecaliximab 150 mg | Placebo |
|---|---|---|---|
| Percentage of Participants That Achieve DAS28(CRP) ≤ 3.2 at Week 12 | 0 | 0 | 0 |
The DAS28 score is a measure of the participant's disease activity calculated using the tender joint counts (28 joints), swollen joint counts (28 joints), Patient's Global Assessment of Disease Activity (visual analog scale: 0 = no disease activity to 100 = maximum disease activity), and CRP for a total possible score of 1 to 9.4. Higher values indicate higher disease activity. A negative change from baseline indicates improvement.
| percentage of participants | Andecaliximab 300 mg | Andecaliximab 150 mg | Placebo |
|---|---|---|---|
| Percentage of Participants That Achieve DAS28(CRP) < 2.6 at Week 12 | 0 | 0 | 0 |
The plasma concentrations of andecaliximab were not collected and were not analyzed.
No measurements were reported for this outcome.
Collected over Baseline up to the last dose date (maximum: 127 days) plus 30 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Andecaliximab 300 mg (Double-Blind) | 0/5 (0%) | 0/5 (0%) | 3/5 (60%) |
| Andecaliximab 150 mg (Double-Blind) | 0/5 (0%) | 0/5 (0%) | 2/5 (40%) |
| Placebo (Double-Blind) | 0/5 (0%) | 0/5 (0%) | 2/5 (40%) |
| Andecaliximab 300 mg (Open-Label) | 0/6 (0%) | 1/6 (16.7%) | 2/6 (33.3%) |
| Event | Andecaliximab 300 mg (Double-Blind) | Andecaliximab 150 mg (Double-Blind) | Placebo (Double-Blind) | Andecaliximab 300 mg (Open-Label) |
|---|---|---|---|---|
| Pelvic painReproductive system and breast disorders | 0/5 | 0/5 | 0/5 | 1/6 |
| Event | Andecaliximab 300 mg (Double-Blind) | Andecaliximab 150 mg (Double-Blind) | Placebo (Double-Blind) | Andecaliximab 300 mg (Open-Label) |
|---|---|---|---|---|
| NauseaGastrointestinal disorders | 0/5 | 1/5 | 0/5 | 1/6 |
| FatigueGeneral disorders | 1/5 | 0/5 | 0/5 | 0/6 |
| InfluenzaInfections and infestations | 0/5 | 1/5 | 0/5 | 0/6 |
| Upper respiratory tract infectionInfections and infestations | 0/5 | 1/5 | 1/5 | 0/6 |
| White blood cell count decreasedInvestigations | 0/5 | 1/5 | 0/5 | 0/6 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 1/5 | 0/5 | 0/5 | 0/6 |
| HeadacheNervous system disorders | 0/5 | 1/5 | 0/5 | 1/6 |
| AnxietyPsychiatric disorders | 1/5 | 0/5 | 0/5 | 0/6 |
| Rash papularSkin and subcutaneous tissue disorders | 0/5 | 0/5 | 1/5 | 0/6 |
| Abdominal pain upperGastrointestinal disorders | 0/5 | 0/5 | 0/5 | 1/6 |
Safety Analysis Set: participants who received at least 1 dose of study drug
| Age, Continuous(years) | Andecaliximab 300 mg | Andecaliximab 150 mg | Placebo | Total |
|---|---|---|---|---|
| Mean | 54 ± 16.3 | 57 ± 9.3 | 58 ± 5.6 | 56 ± 10.6 |
| Sex: Female, Male(Participants) | Andecaliximab 300 mg | Andecaliximab 150 mg | Placebo | Total |
|---|---|---|---|---|
| Female | 3 | 4 | 4 | 11 |
| Male | 2 | 1 | 1 | 4 |
| Ethnicity (NIH/OMB)(Participants) | Andecaliximab 300 mg | Andecaliximab 150 mg | Placebo | Total |
|---|---|---|---|---|
| Hispanic or Latino | 0 | 2 | 0 | 2 |
| Not Hispanic or Latino | 5 | 3 | 5 | 13 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Andecaliximab 300 mg | Andecaliximab 150 mg | Placebo | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 2 | 0 | 1 | 3 |
| White | 3 | 5 | 4 | 12 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Disease Activity Score C-reactive Protein (DAS28(CRP))(units on a scale) | Andecaliximab 300 mg | Andecaliximab 150 mg | Placebo | Total |
|---|---|---|---|---|
| Mean | 5.79 ± 0.814 | 5.90 ± 0.752 | 5.69 ± 0.887 | 5.79 ± 0.764 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Dec 2016 to primary completion in Jun 2017, 6 months.
Results were first posted in Jun 2018, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in May 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Andecaliximab